Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer

被引:16
|
作者
Park, Ji Soo [1 ]
Lee, Seung-Tae [1 ,3 ]
Nam, Eun Ji [1 ,4 ]
Han, Jung Woo [1 ,5 ]
Lee, Jung-Yun [1 ,4 ]
Kim, Jieun [6 ]
Kim, Tae Il [1 ,7 ]
Park, Hyung Seok [1 ,2 ]
机构
[1] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Canc Prevent Ctr,Hereditary Canc Clin, Seoul, South Korea
[2] Yonsei Univ, Coll Med, Dept Surg, 50-1 Yonsei Ro, Seoul 03722, South Korea
[3] Yonsei Univ, Coll Med, Dept Lab Med, Seoul, South Korea
[4] Yonsei Univ, Coll Med, Inst Womens Life Med Sci, Dept Obstet & Gynecol,Womens Canc Clin, Seoul, South Korea
[5] Yonsei Univ, Coll Med, Dept Pediat, Seoul, South Korea
[6] Soonchunhyang Univ, Sch Med, Dept Lab Med, Seoul, South Korea
[7] Yonsei Univ, Coll Med, Dept Internal Med, Div Gastroenterol, Seoul, South Korea
来源
BMC CANCER | 2018年 / 18卷
基金
新加坡国家研究基金会;
关键词
Breast neoplasms; Neoplastic Syndromes; Hereditary; Beyond BRCA1/2; Multigene panel; Next generation sequencing; OVARIAN-CANCER; PANEL; WOMEN;
D O I
10.1186/s12885-017-3940-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: We evaluated the incidence and spectrum of pathogenic and likely pathogenic variants of cancer susceptibility genes in BRCA1/2 mutation-negative Korean patients with a high risk for hereditary breast cancer using a comprehensive multigene panel that included 35 cancer susceptibility genes. Methods: Samples from 120 patients who were negative for BRCA1/2 mutations, but had been diagnosed with breast cancer that was likely hereditary, were prospectively evaluated for the prevalence of high-penetrance and moderate-penetrance germline mutations. Results: Nine patients (7.5%) had at least one pathogenic or likely pathogenic variant. Ten variants were identified in these patients: TP53 in two patients, PALB2 in three patients, BARD1 in two patients, BRIP1 in two patients, and MRE11A in one patient. We also identified 30 types of 139 variants of unknown significance (VUS). High-penetrance germline mutations, including TP53 and PALB2, tended to occur with high frequency in young (< 35 years) breast cancer patients (4/19, 21.1%) than in those diagnosed with breast cancer at >= 35 years of age (1/101, 1.0%; p = 0.003). Conclusions: These combined results demonstrate that multigene panels offer an alternative strategy for identifying veiled pathogenic and likely pathogenic mutations in breast cancer susceptibility genes.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer
    Ji Soo Park
    Seung-Tae Lee
    Eun Ji Nam
    Jung Woo Han
    Jung-Yun Lee
    Jieun Kim
    Tae Il Kim
    Hyung Seok Park
    [J]. BMC Cancer, 18
  • [2] The prevalence of mutations of breast cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with a high risk for hereditary breast cancer
    Park, H.
    Park, J.
    Nam, E.
    Han, J.
    Kim, J.
    Kim, T.
    Cho, Y.
    [J]. BREAST, 2017, 32 : S130 - S130
  • [3] Analysis of BRIP1 Variants among Korean Patients with BRCA1/2 Mutation-Negative High-Risk Breast Cancer
    Kim, Haeyoung
    Cho, Dae-Yeon
    Choi, Doo Ho
    Jung, Gee Hue
    Shin, Inkyung
    Park, Won
    Huh, Seung Jae
    Nam, Seok Jin
    Lee, Jeong Eon
    Gil, Won Ho
    Kim, Seok Won
    [J]. CANCER RESEARCH AND TREATMENT, 2016, 48 (03): : 955 - 961
  • [4] The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients
    van Luttikhuizen, J. L.
    Schubert, S.
    Auber, B.
    Schmidt, G.
    Hofmann, W.
    Penkert, J.
    Davenport, C. F.
    Hille-Betz, U.
    Wendeburg, L.
    Bublitz, J.
    Tauscher, M.
    Hackmann, K.
    Schroeck, E.
    Scholz, C.
    Wallaschek, H.
    Schlegelberger, B.
    Illig, T.
    Steinemann, D.
    [J]. EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 1569 - 1569
  • [5] Candidate gene analysis of BRCA1/2 mutation-negative high-risk Russian breast cancer patients
    Sokolenko, Anna P.
    Preobrazhenskaya, Elena V.
    Aleksakhina, Svetlana N.
    Iyevleva, Aglaya G.
    Mitiushkina, Natalia V.
    Zaitseva, Olga A.
    Yatsuk, Olga S.
    Tiurin, Vladislav I.
    Strelkova, Tatiana N.
    Togo, Alexandr V.
    Imyanitov, Evgeny N.
    [J]. CANCER LETTERS, 2015, 359 (02) : 259 - 261
  • [6] Risk of ovarian cancer in BRCA1 and BRCA2 mutation negative hereditary breast cancer families
    Kauff, ND
    Mitra, N
    Robson, ME
    Hurley, KE
    Chuai, S
    Goldfrank, D
    Wadsworth, E
    Lee, J
    Cigler, T
    Borgen, PI
    Norton, L
    Barakat, RR
    Offit, K
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (18) : 1382 - 1384
  • [7] OLA1 gene sequencing in patients with BRCA1/2 mutation-negative suspected hereditary breast and ovarian cancer
    Masanobu Takahashi
    Natsuko Chiba
    Hideki Shimodaira
    Yuki Yoshino
    Takahiro Mori
    Makiko Sumii
    Tadashi Nomizu
    Chikashi Ishioka
    [J]. Breast Cancer, 2017, 24 : 336 - 340
  • [8] OLA1 gene sequencing in patients with BRCA1/2 mutation-negative suspected hereditary breast and ovarian cancer
    Takahashi, Masanobu
    Chiba, Natsuko
    Shimodaira, Hideki
    Yoshino, Yuki
    Mori, Takahiro
    Sumii, Makiko
    Nomizu, Tadashi
    Ishioka, Chikashi
    [J]. BREAST CANCER, 2017, 24 (02) : 336 - 340
  • [9] Breast cancer risk in mutation-negative members of known BRCA1/2 mutation-positive families
    Korde, L. A.
    Mueller, C. M.
    Nichols, K.
    Loud, J. T.
    Struewing, J.
    Greene, M. H.
    Mai, P. L.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 134S - 134S
  • [10] Implication and Influence of Multigene Panel Testing with Genetic Counseling in Korean Patients with BRCA1/2 Mutation-Negative Breast Cancer
    Park, Ji Soo
    Shin, Saeam
    Lee, Yoon Jung
    Lee, Seung-Tae
    Nam, Eun Ji
    Han, Jung Woo
    Lee, Sun Hwa
    Kim, Tae Il
    Park, Hyung Seok
    [J]. CANCER RESEARCH AND TREATMENT, 2022, 54 (04): : 1099 - 1110